Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors
NCT00003198 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2013-06-27
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of chemotherapy with ifosfamide and topotecan in treating patients with refractory solid tumors.
Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
Interventions
- DRUG
-
ifosfamide
- DRUG
-
topotecan hydrochloride
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
David R. Spriggs, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-11-30
- Primary Completion
- 2000-05-31
- Completion
- 2000-05-31
Countries
- United States
Study Locations
More Related Trials
-
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
NCT01502410 ·Status: COMPLETED ·Phase: PHASE2
-
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
NCT01159301 ·Status: TERMINATED ·Phase: PHASE1
-
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
NCT00244972 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
NCT02050919 ·Status: COMPLETED ·Phase: PHASE2
-
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
NCT01450384 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
NCT00118170 ·Status: COMPLETED ·Phase: PHASE1
-
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
NCT00066612 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT00103259 ·Status: COMPLETED ·Phase: PHASE2
-
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00084786 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib in Treating Patients With Advanced Malignant Solid Tumors
NCT00810394 ·Status: COMPLETED ·Phase: PHASE2
-
Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
NCT00096317 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
NCT00004065 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
NCT01324310 ·Status: COMPLETED ·Phase: PHASE1
-
ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma
NCT00003989 ·Status: COMPLETED ·Phase: PHASE2
-
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
NCT01198184 ·Status: COMPLETED ·Phase: PHASE1
-
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NCT03108131 ·Status: COMPLETED ·Phase: PHASE2
-
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
NCT01303341 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
NCT01497444 ·Status: COMPLETED ·Phase: PHASE1
-
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
NCT00031941 ·Status: COMPLETED ·Phase: PHASE1
-
Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations
NCT01531361 ·Status: COMPLETED ·Phase: PHASE1
-
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
NCT00880542 ·Status: TERMINATED ·Phase: PHASE2
-
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
NCT01218620 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma
NCT00541840 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
NCT00003856 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments
NCT00920205 ·Status: COMPLETED ·Phase: PHASE1